Abstract
An early pathological process affecting the brain of Alzheimer’s disease (AD) is the reactivation of the cell cycle in neurons followed by somatic neuronal tetraploidization (NT). NT also increases with age, and ageing has been shown to correlate with the accumulation of DNA somatic mutations. In this study, we have evaluated the presence of somatic mutations including single nucleotide variants (SNVs) and indels in genomic DNA from tetraploid neurons obtained from the parietal cortex of AD patients, compared with diploid neurons from control individuals and AD patients. Here we show that, in contrast to somatic indels, the proportion of somatic SNVs (sSNVs) significantly increases in the exome of tetraploid neurons, having increased levels of T to C (A to G) transitions, a type of mutation that is associated with oxidative stress. This finding correlates with the over-representation of sSNVs in genes involved in oxidative stress response and DNA repair, suggesting that these alterations exacerbate oxidative DNA damage in tetraploid neurons. sSNVs affecting cancer-related (CR) genes showed a greater molecular pathogenicity score compared with those from a random sample of genes. We propose that neuronal tetraploidy is stochastically triggered through a CR mechanism in neurons whose DNA repair genes become mutated in an oxidative stress scenario. This mechanism likely participates in the etiology of AD.
Competing Interest Statement
Jose; M. Frade is a shareholder (5.42 & equity ownership) of Tetraneuron S.L., a biotech company exploiting his patent on the blockade of neuronal tetraploidy by E2F4DN as a therapeutic approach against AD; Noelia Lopez-Sanchez works for Tetraneuron S.L.; Alberto Rabano declares no competing interests.
Funding Statement
This study has been funded by the Ministerio de Ciencia e Innovacion, grant numbers RTI2018-095030-B-I00 and PID2021-128473OB-I00, supported by MCIN/AEI/10.13039/501100011033 and ERDF A way of making Europe
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the Scientific Committee of CIEN Foundation Brain Tissue Bank and the Ethics Committee of Consejo Superior de Investigaciones Cientificas. Written informed consent for brain removal after death for diagnostic and research purposes, including publication, was obtained from brain donors and/or next of kin.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors. Whole genome sequencing data will be deposited in the National Center for Biotechnology Information Gene Expression Omnibus (GEO) database before this preprint is published as an article.
